Oncocyte Corp
For the period ended Mar 31, 2024. Filed May 15, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 15, 2024
IMDX$2.47-1.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME
| Three Months Ended | ||
|---|---|---|
| March 31, | ||
| 2024 | 2023 | |
| Net (loss) income | $(9,129) | $3,033 |
| Foreign currency translation adjustments | (9) | 4 |
| Comprehensive (loss) income | $(9,138) | $3,037 |
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF SERIES A REDEEMABLE CONVERTIBLE PREFERRED STOCK AND SHAREHOLDERS’ EQUITY
| Series A Redeemable Convertible Preferred Stock · Common Stock · Accumulated Other Comprehensive · Accumulated · Total Shareholders’ | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Income | Deficit | Equity | |
| Balance at December 31, 2023 | 5 | $5,126 | 8,261 | $310,295 | $49 | $(289,876) | $20,468 |
| Net Loss | - | - | - | - | - | (9,129) | (9,129) |
| Foreign currency translation adjustment | - | - | - | - | (9) | - | (9) |
| Stock-based compensation | - | - | - | 418 | - | - | 418 |
| Vesting of bonus awards | - | - | - | 10 | - | - | 10 |
| Shares issued for consultant services | - | - | 12 | 36 | - | - | 36 |
| Accretion of Series A convertible preferred stock to redemption value | - | 206 | - | (206) | - | - | (206) |
| Balance at March 31, 2024 | 5 | $5,332 | 8,273 | $310,553 | $40 | $(299,005) | $11,588 |
| Series A Redeemable Convertible Preferred Stock · Common Stock · Accumulated Other Comprehensive · Accumulated · Total Shareholders’ | |||||||
|---|---|---|---|---|---|---|---|
| Shares | Amount | Shares | Amount | Income | Deficit | Equity | |
| Balance at December 31, 2022 | 6 | $5,302 | 5,932 | $294,929 | $39 | $(260,676) | $34,292 |
| Cumulative change in accounting principle (Note 2) | - | - | - | - | - | (1,419) | (1,419) |
| Balance at January 1, 2023, as adjusted | 6 | 5,302 | 5,932 | 294,929 | 39 | (262,095) | 32,873 |
| Net income | - | - | - | - | - | 3,033 | 3,033 |
| Foreign currency translation adjustment | - | - | - | - | 4 | - | 4 |
| Stock-based compensation | - | - | - | 834 | - | - | 834 |
| Shares issued upon vesting of RSUs | - | - | 31 | - | - | - | - |
| Accretion of Series A convertible preferred stock to redemption value | - | 230 | - | (230) | - | - | (230) |
| Balance at March 31, 2023 | 6 | $5,532 | 5,963 | $295,533 | $43 | $(259,062) | $36,514 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.